SlideShare a Scribd company logo
肺  癌 LUNG CANCER 中山大学肿瘤医院 王 思 愚
Lung cancer – China incidence and mortality rates (1990-2009) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
 
lung cancer cases diagnosed in Cancer Center of Sun Yat-sen University
lung cancer cases diagnosed in Cancer Center of Sun Yat-sen University
Etiology of Lung Cancer ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The risk of lung cancer after stoping smoking Garfinkel L, Silverberg E.  CA Cancer J Clin.  1991;41:137-145.
Classifications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Squamous Non-squamous
 
Clinical Manifestations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical Manifestations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
Diagnosis of lung cancer requires: ,[object Object],[object Object],[object Object],[object Object]
 
Physical examinations ,[object Object],[object Object],[object Object]
Physical examinations ,[object Object],[object Object]
Chest X-ray  ,[object Object]
chest X-ray ,[object Object]
 
 
Lung cancer on CT  ,[object Object],[object Object],[object Object],[object Object]
 
Bronchoscopy  ,[object Object],[object Object]
Transbronchial lung biopsy ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
2008 年 8 月 28 日
Bronchoscopy
Pathology  NSCLC: squamous cell carcinoma
2008 年 11 月 19 日
What should we do before treament ? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Staging of lung cancer ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Stage process ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Stage grouping Mountain   CF.  Chest.  1997;111:1710-1717. IIIB IIIB IIIB IIIB N3 IIIB IIIA IIIA IIIA N2 IIIB IIIA IIB IIA N1 IIIB IIB IB IA N0 T4 T3 T2 T1
 
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Surgery ,[object Object],[object Object],[object Object],[object Object]
Surgery ,[object Object],[object Object],[object Object]
5-years survival rate after surgery Mountain CF ,  Chest  1997. TNM stage 5 YS ( clinical stage ) 5YS ( pathologic stage ) T1 N0 M0 n=687  61% n=511  67% T2 N0 M0 n=1189  38% n=549  57% T1 N1 M0 n=29  34% n=76  55% T2 N1 M0 n=250  24% n=288  39% T3 N0 M0 n=107  22% n=87  38% T3 N1 M0 n=40  9% n=55  25% T1-3 N2 M0 n=471  13% n=344  23% T4 N0-2 M0 n=458  7% NA Any T N3 M0 n=572  3% NA Any T any N M1 n=1427  1% NA
Radiation therapy Radiotherapy plays a major role in the treatment of lung cancer. It is divided into curative treatment and palliative treatment.  It is of proven benefit in controlling bone pain, spinal cord compression, superior vena cava  syndrome and bronchial obstruction.
Chemotherapy ,[object Object],[object Object],[object Object],[object Object],[object Object]
The newest evidence for Adjuvant chemotherapy
2007 update meta-analysis
2007’s ASCO
LACE meta-analysis   : OS HR=0.89 95%CI=0.82-0.96 P=0.005 Pignon JP, et al. J Clin Oncol 2008; 26:3552-3559 100 80 60 40 20 0 1 2 3 4 5 ≥ 6 Time From Randomization (years) Chem. Control 总体生存  (%)
LACE meta-analysis  : DFS HR=0.84 95%CI=0.78-0.91 P<0.001 Pignon JP, et al. J Clin Oncol 2008; 26:3552-3559. Time From Randomization (years) 100 80 60 40 20 0 1 2 3 4 5 ≥ 6 Chem. Control 无病生存  (%)
LACE meta-analysis  : Survival according to type of death. ,[object Object],[object Object],[object Object],Pignon JP, et al. J Clin Oncol 2008; 26:3552-3559.[ 临床肿瘤学杂志中文版  2009; 3(1): 10-17.] 100 80 60 40 20 0 1 2 3 4 5 ≥ 6 Time From Randomization (years) Survival (%) Chem. ( noncancer-related death   ) Cont  (noncancer-related death   ) 化疗 ( 癌症相关死亡 ) 不化疗 ( 癌症相关死亡 )
 
IIIA-N2:Overall survival at 5 years with chemotherapy improved by 12% 31.1% vs 19.1% MS:33m vs 24m
Questions : ,[object Object],[object Object],[object Object],[object Object]
 
Chemotherapy for advanced stage of lung cancer BMJ, 1995
NSCLC Meta-analyses NSCLC Meta-analyses Collaborative Group. JCO 2008; 26:4617-25 .[ 临床肿瘤学杂志中文版  2009; 3(2): 45.] ,[object Object],[object Object],[object Object],HR=0.77 95%CI=0.71-0.83 P≤0.0001 1YS: 29% vs. 20% 1.0 0.8 0.6 0.4 0.2 0 3 6 9 12 15 18 21 24 时间  ( 月 ) 概率 事件数 患者总数 1240 1293 1315 1399 SC+CT 仅 SC
First-line chemotherapy options in NSCLC  (E1594):  comparable efficacy with platinum doublets   Schiller, et al. NEJM 2002 1.0 0.8 0.6 0.4 0.2 0 0 5 10 15 20 25 30 Time (months) Cisplatin/paclitaxel Cisplatin/gemcitabine Cisplatin/docetaxel Carboplatin/paclitaxel Probability of survival Therapeutic plateau: overall survival <12 months
Overall Survival by Histology Non-squamous (n=481) Squamous (n=182) HR=0.70  (95% CI: 0.56-0.88) P  =0.002 HR=1.07 (95% CI: 0.49–0.73) P  =0.678 Survival Probability Time (months)  Time (months)  2009 ASCO Pemetrexed 15.5 mos Pemetrexed 9.9 mos Placebo  10.3 mos Placebo  10.8 mos
Targeted therapy ,[object Object]
 
 
 
晚期非小细胞肺癌 front-line 治疗策略 EGFR 突变者 30 % TKI MST : 20 - 24 月 EGFR 野生者 70 % 腺癌 35 % 鳞癌 35 % 第三代+铂类 10 月 维持治疗 13 月 培美曲塞+铂类: 11.8 月 西妥昔单抗 或贝伐单抗 12 - 16 月 + ERCC1 BRCA1: 选择铂类药物 RRMI :选择 Gemcitabine TS :选择 Pemetrexed
Treatment of Lung Cancer ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
致谢胸科全体家人!

More Related Content

What's hot

SMALL CELL LUNG CANCER (SCLC)
SMALL CELL LUNG CANCER (SCLC)SMALL CELL LUNG CANCER (SCLC)
SMALL CELL LUNG CANCER (SCLC)fondas vakalis
 
Lung Cancer Video1
Lung Cancer Video1Lung Cancer Video1
Lung Cancer Video1
Robert J Miller MD
 
Non Small Cell Lung Cancer
Non Small Cell Lung CancerNon Small Cell Lung Cancer
Non Small Cell Lung Cancerfondas vakalis
 
Lung cancer; epidemiology,etiology and classification
Lung cancer; epidemiology,etiology and classificationLung cancer; epidemiology,etiology and classification
Lung cancer; epidemiology,etiology and classification
docpiash
 
Lung cancer board review lecture
Lung cancer board review lectureLung cancer board review lecture
Lung cancer board review lecture
Amit Jain
 
Lung cancer. Morbidity
Lung cancer. MorbidityLung cancer. Morbidity
Lung cancer. Morbidity
Eneutron
 
Asia's Quiet War on Lung Cancer
Asia's Quiet War on Lung CancerAsia's Quiet War on Lung Cancer
Asia's Quiet War on Lung Cancer
Eden Strategy Institute LLP
 
Dr. Frank Sullivan - Early diagnosis of lung cancer
Dr. Frank Sullivan - Early diagnosis of lung cancerDr. Frank Sullivan - Early diagnosis of lung cancer
Dr. Frank Sullivan - Early diagnosis of lung cancer
pincomm
 
Lung Cancer
Lung Cancer Lung Cancer
Lung Cancer
CoMed
 
Case study adenocarcinoma of the lung
Case study adenocarcinoma of the lungCase study adenocarcinoma of the lung
Case study adenocarcinoma of the lungNiccole Couse
 
Treatment options for lung cancer
Treatment options for lung cancerTreatment options for lung cancer
Treatment options for lung cancer
Faruk Hossain
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
Dr. Yogesh Belagali
 
Advance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer finalAdvance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer finalTauhid Bhuiyan
 
REVIEW OF METHODS FOR DIAGNOSIS OF LUNG CANCER
REVIEW OF METHODS FOR DIAGNOSIS OF LUNG CANCERREVIEW OF METHODS FOR DIAGNOSIS OF LUNG CANCER
REVIEW OF METHODS FOR DIAGNOSIS OF LUNG CANCER
swankyshahir
 
Lung cancer
Lung cancerLung cancer
Lung cancer
Mahesh Dayyala
 
CES2017-02: Lung Cancer
CES2017-02: Lung CancerCES2017-02: Lung Cancer
CES2017-02: Lung Cancer
Mauricio Lema
 
Lung cancer
Lung cancerLung cancer
Lung cancer
jamal turki
 
CES 2016 02 - Lung Cancer
CES 2016 02 - Lung CancerCES 2016 02 - Lung Cancer
CES 2016 02 - Lung Cancer
Mauricio Lema
 

What's hot (20)

Lung cancer
Lung cancerLung cancer
Lung cancer
 
SMALL CELL LUNG CANCER (SCLC)
SMALL CELL LUNG CANCER (SCLC)SMALL CELL LUNG CANCER (SCLC)
SMALL CELL LUNG CANCER (SCLC)
 
Lung Cancer Video1
Lung Cancer Video1Lung Cancer Video1
Lung Cancer Video1
 
Non Small Cell Lung Cancer
Non Small Cell Lung CancerNon Small Cell Lung Cancer
Non Small Cell Lung Cancer
 
Lung cancer; epidemiology,etiology and classification
Lung cancer; epidemiology,etiology and classificationLung cancer; epidemiology,etiology and classification
Lung cancer; epidemiology,etiology and classification
 
Lung cancer board review lecture
Lung cancer board review lectureLung cancer board review lecture
Lung cancer board review lecture
 
Lung cancer. Morbidity
Lung cancer. MorbidityLung cancer. Morbidity
Lung cancer. Morbidity
 
Asia's Quiet War on Lung Cancer
Asia's Quiet War on Lung CancerAsia's Quiet War on Lung Cancer
Asia's Quiet War on Lung Cancer
 
Dr. Frank Sullivan - Early diagnosis of lung cancer
Dr. Frank Sullivan - Early diagnosis of lung cancerDr. Frank Sullivan - Early diagnosis of lung cancer
Dr. Frank Sullivan - Early diagnosis of lung cancer
 
Lung Cancer
Lung Cancer Lung Cancer
Lung Cancer
 
Lungcancer
Lungcancer Lungcancer
Lungcancer
 
Case study adenocarcinoma of the lung
Case study adenocarcinoma of the lungCase study adenocarcinoma of the lung
Case study adenocarcinoma of the lung
 
Treatment options for lung cancer
Treatment options for lung cancerTreatment options for lung cancer
Treatment options for lung cancer
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 
Advance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer finalAdvance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer final
 
REVIEW OF METHODS FOR DIAGNOSIS OF LUNG CANCER
REVIEW OF METHODS FOR DIAGNOSIS OF LUNG CANCERREVIEW OF METHODS FOR DIAGNOSIS OF LUNG CANCER
REVIEW OF METHODS FOR DIAGNOSIS OF LUNG CANCER
 
Lung cancer
Lung cancerLung cancer
Lung cancer
 
CES2017-02: Lung Cancer
CES2017-02: Lung CancerCES2017-02: Lung Cancer
CES2017-02: Lung Cancer
 
Lung cancer
Lung cancerLung cancer
Lung cancer
 
CES 2016 02 - Lung Cancer
CES 2016 02 - Lung CancerCES 2016 02 - Lung Cancer
CES 2016 02 - Lung Cancer
 

Similar to 10 lung cancer

Rare Solid Cancers: An Introduction - Slide 16 - R.A. Stahel - Rare thoracic ...
Rare Solid Cancers: An Introduction - Slide 16 - R.A. Stahel - Rare thoracic ...Rare Solid Cancers: An Introduction - Slide 16 - R.A. Stahel - Rare thoracic ...
Rare Solid Cancers: An Introduction - Slide 16 - R.A. Stahel - Rare thoracic ...European School of Oncology
 
CES202101 - Clase 12 - Cáncer de pulmón (1/2)
CES202101 - Clase 12 - Cáncer de pulmón (1/2) CES202101 - Clase 12 - Cáncer de pulmón (1/2)
CES202101 - Clase 12 - Cáncer de pulmón (1/2)
Mauricio Lema
 
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGSLUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
Kanhu Charan
 
Neuroendocrine tumors in 2015
Neuroendocrine tumors in 2015Neuroendocrine tumors in 2015
Neuroendocrine tumors in 2015
Mohamed Abdulla
 
Early Stage Nsclc The Role Of Chemotherapy
Early Stage Nsclc The Role Of ChemotherapyEarly Stage Nsclc The Role Of Chemotherapy
Early Stage Nsclc The Role Of Chemotherapyfondas vakalis
 
C:\Documents And Settings\User\Desktop\Head And Neck
C:\Documents And Settings\User\Desktop\Head And NeckC:\Documents And Settings\User\Desktop\Head And Neck
C:\Documents And Settings\User\Desktop\Head And Neck
Gamal Abdul Hamid
 
SBRT/SABR for Early Stage Lung Cancer: A Brief Overview
SBRT/SABR for Early Stage Lung Cancer: A Brief OverviewSBRT/SABR for Early Stage Lung Cancer: A Brief Overview
SBRT/SABR for Early Stage Lung Cancer: A Brief Overview
Todd Scarbrough
 
Positron Emission Tomography In Oncology
Positron Emission Tomography In OncologyPositron Emission Tomography In Oncology
Positron Emission Tomography In Oncologyfondas vakalis
 
Adjuvant systemic therapy in resectable non-small cell lung cancer, Moh'd sha...
Adjuvant systemic therapy in resectable non-small cell lung cancer, Moh'd sha...Adjuvant systemic therapy in resectable non-small cell lung cancer, Moh'd sha...
Adjuvant systemic therapy in resectable non-small cell lung cancer, Moh'd sha...
Moh'd sharshir
 
Surgical persrective in lung cancer
Surgical persrective in lung cancerSurgical persrective in lung cancer
Surgical persrective in lung cancerHarilal Nambiar
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 
CES2021 - Clase 13 - Cáncer de pulmón (2/2)
CES2021 - Clase 13 - Cáncer de pulmón (2/2)CES2021 - Clase 13 - Cáncer de pulmón (2/2)
CES2021 - Clase 13 - Cáncer de pulmón (2/2)
Mauricio Lema
 
Prostate Cancer . Castration resistance
Prostate Cancer . Castration resistanceProstate Cancer . Castration resistance
Prostate Cancer . Castration resistance
Luis Toache
 
Nsclc port
Nsclc portNsclc port
Nsclc port
Sreekanth Nallam
 

Similar to 10 lung cancer (20)

Rare Solid Cancers: An Introduction - Slide 16 - R.A. Stahel - Rare thoracic ...
Rare Solid Cancers: An Introduction - Slide 16 - R.A. Stahel - Rare thoracic ...Rare Solid Cancers: An Introduction - Slide 16 - R.A. Stahel - Rare thoracic ...
Rare Solid Cancers: An Introduction - Slide 16 - R.A. Stahel - Rare thoracic ...
 
Update Nsclc
Update NsclcUpdate Nsclc
Update Nsclc
 
MCo 2011 - Slide 25 - W. Weder - Surgery
MCo 2011 - Slide 25 - W. Weder - SurgeryMCo 2011 - Slide 25 - W. Weder - Surgery
MCo 2011 - Slide 25 - W. Weder - Surgery
 
CES202101 - Clase 12 - Cáncer de pulmón (1/2)
CES202101 - Clase 12 - Cáncer de pulmón (1/2) CES202101 - Clase 12 - Cáncer de pulmón (1/2)
CES202101 - Clase 12 - Cáncer de pulmón (1/2)
 
6 lungcancer
6 lungcancer6 lungcancer
6 lungcancer
 
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGSLUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
 
Neuroendocrine tumors in 2015
Neuroendocrine tumors in 2015Neuroendocrine tumors in 2015
Neuroendocrine tumors in 2015
 
Early Stage Nsclc The Role Of Chemotherapy
Early Stage Nsclc The Role Of ChemotherapyEarly Stage Nsclc The Role Of Chemotherapy
Early Stage Nsclc The Role Of Chemotherapy
 
SBRTweb.nearmc
SBRTweb.nearmcSBRTweb.nearmc
SBRTweb.nearmc
 
C:\Documents And Settings\User\Desktop\Head And Neck
C:\Documents And Settings\User\Desktop\Head And NeckC:\Documents And Settings\User\Desktop\Head And Neck
C:\Documents And Settings\User\Desktop\Head And Neck
 
SBRT/SABR for Early Stage Lung Cancer: A Brief Overview
SBRT/SABR for Early Stage Lung Cancer: A Brief OverviewSBRT/SABR for Early Stage Lung Cancer: A Brief Overview
SBRT/SABR for Early Stage Lung Cancer: A Brief Overview
 
Positron Emission Tomography In Oncology
Positron Emission Tomography In OncologyPositron Emission Tomography In Oncology
Positron Emission Tomography In Oncology
 
Lung ca
Lung caLung ca
Lung ca
 
Dugo Iasgo 09
Dugo Iasgo 09Dugo Iasgo 09
Dugo Iasgo 09
 
Adjuvant systemic therapy in resectable non-small cell lung cancer, Moh'd sha...
Adjuvant systemic therapy in resectable non-small cell lung cancer, Moh'd sha...Adjuvant systemic therapy in resectable non-small cell lung cancer, Moh'd sha...
Adjuvant systemic therapy in resectable non-small cell lung cancer, Moh'd sha...
 
Surgical persrective in lung cancer
Surgical persrective in lung cancerSurgical persrective in lung cancer
Surgical persrective in lung cancer
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 
CES2021 - Clase 13 - Cáncer de pulmón (2/2)
CES2021 - Clase 13 - Cáncer de pulmón (2/2)CES2021 - Clase 13 - Cáncer de pulmón (2/2)
CES2021 - Clase 13 - Cáncer de pulmón (2/2)
 
Prostate Cancer . Castration resistance
Prostate Cancer . Castration resistanceProstate Cancer . Castration resistance
Prostate Cancer . Castration resistance
 
Nsclc port
Nsclc portNsclc port
Nsclc port
 

More from Sumit Prajapati

Pericardial abnormal findings
Pericardial abnormal findingsPericardial abnormal findings
Pericardial abnormal findingsSumit Prajapati
 
Diagnostic radiology of cardiovascular 2009
Diagnostic radiology of cardiovascular 2009Diagnostic radiology of cardiovascular 2009
Diagnostic radiology of cardiovascular 2009Sumit Prajapati
 
20100603 acute glomerulonephritis
20100603 acute glomerulonephritis20100603 acute glomerulonephritis
20100603 acute glomerulonephritisSumit Prajapati
 
1 introduction of epidmiology
1 introduction of epidmiology1 introduction of epidmiology
1 introduction of epidmiologySumit Prajapati
 
Anesthesia outside the operating room
Anesthesia outside the operating roomAnesthesia outside the operating room
Anesthesia outside the operating roomSumit Prajapati
 
Neonatal cold injury syndrome
Neonatal cold injury syndromeNeonatal cold injury syndrome
Neonatal cold injury syndromeSumit Prajapati
 
C:\Documents And Settings\Administrator\桌面\13 Uri
C:\Documents And Settings\Administrator\桌面\13 UriC:\Documents And Settings\Administrator\桌面\13 Uri
C:\Documents And Settings\Administrator\桌面\13 UriSumit Prajapati
 
C:\documents and settings\administrator\桌面\11 fluid therapy
C:\documents and settings\administrator\桌面\11 fluid therapyC:\documents and settings\administrator\桌面\11 fluid therapy
C:\documents and settings\administrator\桌面\11 fluid therapySumit Prajapati
 
Administration of general anesthesia
Administration of general anesthesiaAdministration of general anesthesia
Administration of general anesthesiaSumit Prajapati
 
1 evaluating the patient before the anesthesia(2009.2.23 27)
1 evaluating the patient before the anesthesia(2009.2.23 27)1 evaluating the patient before the anesthesia(2009.2.23 27)
1 evaluating the patient before the anesthesia(2009.2.23 27)Sumit Prajapati
 
9 tuberculosis tanweiping
9 tuberculosis tanweiping9 tuberculosis tanweiping
9 tuberculosis tanweipingSumit Prajapati
 

More from Sumit Prajapati (20)

Pericardial abnormal findings
Pericardial abnormal findingsPericardial abnormal findings
Pericardial abnormal findings
 
Diagnostic radiology of cardiovascular 2009
Diagnostic radiology of cardiovascular 2009Diagnostic radiology of cardiovascular 2009
Diagnostic radiology of cardiovascular 2009
 
20100603 acute glomerulonephritis
20100603 acute glomerulonephritis20100603 acute glomerulonephritis
20100603 acute glomerulonephritis
 
05 diagnostic tests cwq
05 diagnostic tests cwq05 diagnostic tests cwq
05 diagnostic tests cwq
 
3 cross sectional study
3 cross sectional study3 cross sectional study
3 cross sectional study
 
3 cross sectional study
3 cross sectional study3 cross sectional study
3 cross sectional study
 
2.epidemilogic measures
2.epidemilogic measures2.epidemilogic measures
2.epidemilogic measures
 
1 introduction of epidmiology
1 introduction of epidmiology1 introduction of epidmiology
1 introduction of epidmiology
 
Anesthesia outside the operating room
Anesthesia outside the operating roomAnesthesia outside the operating room
Anesthesia outside the operating room
 
Neonatal septicemia
Neonatal septicemiaNeonatal septicemia
Neonatal septicemia
 
Neonatal cold injury syndrome
Neonatal cold injury syndromeNeonatal cold injury syndrome
Neonatal cold injury syndrome
 
C:\Documents And Settings\Administrator\桌面\13 Uri
C:\Documents And Settings\Administrator\桌面\13 UriC:\Documents And Settings\Administrator\桌面\13 Uri
C:\Documents And Settings\Administrator\桌面\13 Uri
 
C:\documents and settings\administrator\桌面\11 fluid therapy
C:\documents and settings\administrator\桌面\11 fluid therapyC:\documents and settings\administrator\桌面\11 fluid therapy
C:\documents and settings\administrator\桌面\11 fluid therapy
 
08 pain lishangrong 2
08 pain lishangrong 208 pain lishangrong 2
08 pain lishangrong 2
 
Administration of general anesthesia
Administration of general anesthesiaAdministration of general anesthesia
Administration of general anesthesia
 
5 regional anesthesia
5 regional anesthesia5 regional anesthesia
5 regional anesthesia
 
3 general anethesia
3 general anethesia3 general anethesia
3 general anethesia
 
2 safety in anesthesia
2 safety in anesthesia2 safety in anesthesia
2 safety in anesthesia
 
1 evaluating the patient before the anesthesia(2009.2.23 27)
1 evaluating the patient before the anesthesia(2009.2.23 27)1 evaluating the patient before the anesthesia(2009.2.23 27)
1 evaluating the patient before the anesthesia(2009.2.23 27)
 
9 tuberculosis tanweiping
9 tuberculosis tanweiping9 tuberculosis tanweiping
9 tuberculosis tanweiping
 

Recently uploaded

June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
DRUGS AND ITS classification slide share
DRUGS AND ITS classification slide shareDRUGS AND ITS classification slide share
DRUGS AND ITS classification slide share
taiba qazi
 
Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School DistrictPride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
David Douglas School District
 
Digital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments UnitDigital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments Unit
chanes7
 
PIMS Job Advertisement 2024.pdf Islamabad
PIMS Job Advertisement 2024.pdf IslamabadPIMS Job Advertisement 2024.pdf Islamabad
PIMS Job Advertisement 2024.pdf Islamabad
AyyanKhan40
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
PCOS corelations and management through Ayurveda.
PCOS corelations and management through Ayurveda.PCOS corelations and management through Ayurveda.
PCOS corelations and management through Ayurveda.
Dr. Shivangi Singh Parihar
 
The Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collectionThe Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collection
Israel Genealogy Research Association
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
amberjdewit93
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
How to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP ModuleHow to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP Module
Celine George
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
How to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold MethodHow to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold Method
Celine George
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
deeptiverma2406
 
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
NelTorrente
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
Top five deadliest dog breeds in America
Top five deadliest dog breeds in AmericaTop five deadliest dog breeds in America
Top five deadliest dog breeds in America
Bisnar Chase Personal Injury Attorneys
 
Group Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana BuscigliopptxGroup Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana Buscigliopptx
ArianaBusciglio
 

Recently uploaded (20)

June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
DRUGS AND ITS classification slide share
DRUGS AND ITS classification slide shareDRUGS AND ITS classification slide share
DRUGS AND ITS classification slide share
 
Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School DistrictPride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
 
Digital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments UnitDigital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments Unit
 
PIMS Job Advertisement 2024.pdf Islamabad
PIMS Job Advertisement 2024.pdf IslamabadPIMS Job Advertisement 2024.pdf Islamabad
PIMS Job Advertisement 2024.pdf Islamabad
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
PCOS corelations and management through Ayurveda.
PCOS corelations and management through Ayurveda.PCOS corelations and management through Ayurveda.
PCOS corelations and management through Ayurveda.
 
The Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collectionThe Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collection
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
How to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP ModuleHow to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP Module
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
How to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold MethodHow to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold Method
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
 
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
Top five deadliest dog breeds in America
Top five deadliest dog breeds in AmericaTop five deadliest dog breeds in America
Top five deadliest dog breeds in America
 
Group Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana BuscigliopptxGroup Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana Buscigliopptx
 

10 lung cancer

  • 1. 肺 癌 LUNG CANCER 中山大学肿瘤医院 王 思 愚
  • 2.
  • 3.  
  • 4.  
  • 5. lung cancer cases diagnosed in Cancer Center of Sun Yat-sen University
  • 6. lung cancer cases diagnosed in Cancer Center of Sun Yat-sen University
  • 7.
  • 8. The risk of lung cancer after stoping smoking Garfinkel L, Silverberg E. CA Cancer J Clin. 1991;41:137-145.
  • 9.
  • 10.  
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.  
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.  
  • 21.  
  • 22.
  • 23.  
  • 24.
  • 25.
  • 26.  
  • 27. 2008 年 8 月 28 日
  • 29. Pathology NSCLC: squamous cell carcinoma
  • 30. 2008 年 11 月 19 日
  • 31.
  • 32.
  • 33.
  • 34. Stage grouping Mountain CF. Chest. 1997;111:1710-1717. IIIB IIIB IIIB IIIB N3 IIIB IIIA IIIA IIIA N2 IIIB IIIA IIB IIA N1 IIIB IIB IB IA N0 T4 T3 T2 T1
  • 35.  
  • 36.
  • 37.
  • 38.
  • 39. 5-years survival rate after surgery Mountain CF , Chest 1997. TNM stage 5 YS ( clinical stage ) 5YS ( pathologic stage ) T1 N0 M0 n=687 61% n=511 67% T2 N0 M0 n=1189 38% n=549 57% T1 N1 M0 n=29 34% n=76 55% T2 N1 M0 n=250 24% n=288 39% T3 N0 M0 n=107 22% n=87 38% T3 N1 M0 n=40 9% n=55 25% T1-3 N2 M0 n=471 13% n=344 23% T4 N0-2 M0 n=458 7% NA Any T N3 M0 n=572 3% NA Any T any N M1 n=1427 1% NA
  • 40. Radiation therapy Radiotherapy plays a major role in the treatment of lung cancer. It is divided into curative treatment and palliative treatment. It is of proven benefit in controlling bone pain, spinal cord compression, superior vena cava syndrome and bronchial obstruction.
  • 41.
  • 42. The newest evidence for Adjuvant chemotherapy
  • 45. LACE meta-analysis : OS HR=0.89 95%CI=0.82-0.96 P=0.005 Pignon JP, et al. J Clin Oncol 2008; 26:3552-3559 100 80 60 40 20 0 1 2 3 4 5 ≥ 6 Time From Randomization (years) Chem. Control 总体生存 (%)
  • 46. LACE meta-analysis : DFS HR=0.84 95%CI=0.78-0.91 P<0.001 Pignon JP, et al. J Clin Oncol 2008; 26:3552-3559. Time From Randomization (years) 100 80 60 40 20 0 1 2 3 4 5 ≥ 6 Chem. Control 无病生存 (%)
  • 47.
  • 48.  
  • 49. IIIA-N2:Overall survival at 5 years with chemotherapy improved by 12% 31.1% vs 19.1% MS:33m vs 24m
  • 50.
  • 51.  
  • 52. Chemotherapy for advanced stage of lung cancer BMJ, 1995
  • 53.
  • 54. First-line chemotherapy options in NSCLC (E1594): comparable efficacy with platinum doublets Schiller, et al. NEJM 2002 1.0 0.8 0.6 0.4 0.2 0 0 5 10 15 20 25 30 Time (months) Cisplatin/paclitaxel Cisplatin/gemcitabine Cisplatin/docetaxel Carboplatin/paclitaxel Probability of survival Therapeutic plateau: overall survival <12 months
  • 55. Overall Survival by Histology Non-squamous (n=481) Squamous (n=182) HR=0.70 (95% CI: 0.56-0.88) P =0.002 HR=1.07 (95% CI: 0.49–0.73) P =0.678 Survival Probability Time (months) Time (months) 2009 ASCO Pemetrexed 15.5 mos Pemetrexed 9.9 mos Placebo 10.3 mos Placebo 10.8 mos
  • 56.
  • 57.  
  • 58.  
  • 59.  
  • 60. 晚期非小细胞肺癌 front-line 治疗策略 EGFR 突变者 30 % TKI MST : 20 - 24 月 EGFR 野生者 70 % 腺癌 35 % 鳞癌 35 % 第三代+铂类 10 月 维持治疗 13 月 培美曲塞+铂类: 11.8 月 西妥昔单抗 或贝伐单抗 12 - 16 月 + ERCC1 BRCA1: 选择铂类药物 RRMI :选择 Gemcitabine TS :选择 Pemetrexed
  • 61.

Editor's Notes

  1. Garfinkel L, Silverberg E. Lung cancer and smoking trends in the United States over the past 25 years. CA Cancer J Clin. 1991;41:137-145.
  2. Squamous cell carcinoma: These tumours consist of layers of epithelial cells that secrete keratin, and therefore often present as obstructing tumours in the bronchi. They are the most common type of lung cancer representing 30-50% of all cases. The histological type of NSCLC may affect treatment outcome. Non-squamous cell carcinomas were twice as likely as squamous cell carcinomas to recur after surgery in one study (0.088 and 0.042 recurrences per patient per year, respectively), even though all the cancers were the same stage (T1 N0). 1 Bronchoalveolar carcinoma, a sub-type of adenocarcinoma, presents at an earlier stage than other adenocarcinomas, appears to be less aggressive, and is associated with better survival. Early diagnosis and surgical treatment are therefore particularly valuable in nodular bronchoalveolar carcinoma. 2 In contrast with other bronchial carcinomas, survival of patients with bronchoalveolar carcinoma is influenced more by the extent of lung involvement (eg presence of bilateral lesions, production of mucin by tumor cells) than by the extent of lymph node metastases. 3 1. Thomas P, Rubinstein L. Ann Thorac Surg 1990; 49: 242-247. 2. Grover FL, Piantadosi S. Ann Surg 1989; 209: 779-790. 3. Daly RC, et al. Ann Thorac Surg 1991; 51: 368-377.
  3. After obtaining the diagnosis of lung cancer through bronchoscopy, transbronchial needle aspiration, transthoracic needle aspiration, or mediastinoscopy, further diagnostic evaluations are directed at evaluating the extension of the disease. Diagnostic evaluation should include a chest X-ray and chest CT that encompasses the liver and adrenal glands.
  4. Clinical staging of lung cancer helps to determine the extent of disease and stratify patients into similar prognostic and therapeutic categories. An important goal is to separate patients with potentially resectable disease from those who have unresectable disease. The most recent staging system for lung cancer was published in 1997, replacing the 1986 classification. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111:1710-1717.